ReviewPoultry science2026
Review on anticoccidial vaccine development for chickens: Past progress, modern methods, and production bottlenecks.
Review in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poultry coccidiosis is an economically significant intestinal disease caused by parasitic protozoa in the genus Eimeria. Developing Eimeria vaccines is a possible way to control and prevent coccidiosis. This review discusses the different methods and challenges of anticoccidia vaccine production for poultry. The production of anticoccidial vaccines involves several methods with challenges. Live Eimeria vaccines are produced using non-attenuation without any alteration or modifications in terms of pathogenicity, and attenuation methods reduce virulence through serial passage in embryonated eggs or chickens, irradiation, chemicals, heat, and live strains tolerant of ionophores. Both non-attenuation and attenuation methods are challenge, including the need for chickens' infection to produce oocysts, high cost, and quality control tests for ensuring vaccine safety. To minimize the challenge of live vaccine production, use recombinant deoxyribonucleic acid (DNA) technology. Unlike conventional whole-cell vaccines, non-replicating subunits only contain the pathogen antigenic parts for the subunit vaccine and genetic materials for DNA vaccine production and are cloned in the presence of a harmless plasmid vector or with a harmless adjuvant. The genetic and antigenic diversity among and within species of Eimeria, chicken flocks and locations, and complex life cycle of the Eimeria species make the development of DNA and recombinant vaccines extremely difficult. Challenge infection effects in immunized chickens are determined by weight gain, feed conversion efficiency, oocyst production, and intestine lesions, but there is a lack of immunological assays for accurately predicting studies for laboratory and field trials and standard guidelines for modern poultry vaccine production in Eimeria. The production of a safe and effective vaccine against coccidiosis in poultry is crucial for minimizing economic losses and enhancing animal welfare. To select the appropriate anticoccidial vaccine development methods and assess the challenges faced, more research should be done.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.